CellCentric Company
CellCentricвАЩs primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Founded Date:
2003
Last Funding Type:
Venture - Series Unknown
Headquarters:
Cambridge, Cambridgeshire, United Kingdom
Investors Number:
9
Technology:
Data-driven Technologies
Employee Number:
1-10
Industry:
PharmTech
Estimated Revenue:
$10M to $50M
Number Of Exists:
Venture - Series Unknown
Funding Status:
N/A
Investor Type:
Company
Investment Stage:
N/A
Total Funding:
$42.6M